Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation
These data indicated that HRR mutations had no effect on pCR in HER-2 negative patients receiving NAC regardless of hormone receptor status. BRCA1 mutation carriers have a higher rate of pCR and are more benefit from platinum-containing regimen than BRCA2 mutation carriers.
Authors
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Jiayu Wang (ORCID: https://orcid.org/0000-0003-1967-389X)
- Ruigang Cai
- Lei Ji (ORCID: https://orcid.org/0000-0001-8391-9300)
- Qiao Li (ORCID: https://orcid.org/0000-0002-4547-1266)
- Qing Li (ORCID: https://orcid.org/0000-0002-9258-508X)
- Shanshan Chen (ORCID: https://orcid.org/0000-0001-9723-2403)
- Pin Zhang (ORCID: https://orcid.org/0000-0001-8903-3666)
- Ying Fan (ORCID: https://orcid.org/0000-0003-3419-9399)
- Bo Lan (ORCID: https://orcid.org/0000-0003-1289-9327)
- Xi Chen (ORCID: https://orcid.org/0009-0009-4599-5711)
- Yang Luo (ORCID: https://orcid.org/0000-0001-5387-3954)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1080/14796694.2025.2534767
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00